



DPW/AF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hsuan-Yin LAN-HARGEST et al
Serial No. : 10/025,947
Filed : December 26, 2001
Title : HISTONE DEACETYLASE INHIBITORS

Confirmation No. 8464

Group Art Unit 1621
Examiner Paul A. Zucker

U.S. Patent and Trademark Office
220 20th Street South
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

REVOCATION AND NEW POWER OF ATTORNEY

Under 37 CFR §3.73(b), Errant Gene Therapeutics, LLC, certifies that it is the assignee of 100% of the right, title and interest in the patent application identified above by virtue of an assignment from Beacon Laboratories, Inc. to Errant Gene Therapeutics, LLC recorded at the Patent and Trademark Office on November 2, 2004 at Reel 015327, Frame 0839. A copy of the assignment is attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned, whose title is supplied below, is empowered to act on behalf of the assignee.

The undersigned, acting on behalf of the assignee, hereby revokes all powers of attorney previously granted in the application and appoints:

Harold H. Fox Reg. No. 41,498
Stuart T. F. Huang Reg. No. 34,184
D. Douglas Price Reg. No. 24,514
Charles F. Schill..... Reg. No. 27,590
Scott D. Watkins Reg. No. 36,715
Timothy C. Bickham..... Reg. No. 41,618
C. Donald Stevens..... Reg. No. 53,638

of: **CUSTOMER No. 27890**
STEPTOE & JOHNSON LLP
1330 Connecticut Avenue, NW
Washington, DC 20036
Tel: 202-429-3000
Fax: 202-429-3902

with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected therewith.

All correspondence regarding the application should be sent to:

27890

PTO Customer Number

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Date:

Dec. 27 2004



Patrick Girondi
Manager

Errant Gene Therapeutics, LLC